Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Jaffer, Ajani"'
Autor:
Jiahui Jiang, Yunhe Liu, Jiangjiang Qin, Jianfeng Chen, Jingjing Wu, Melissa P. Pizzi, Rossana Lazcano, Kohei Yamashita, Zhiyuan Xu, Guangsheng Pei, Kyung Serk Cho, Yanshuo Chu, Ansam Sinjab, Fuduan Peng, Xinmiao Yan, Guangchun Han, Ruiping Wang, Enyu Dai, Yibo Dai, Bogdan A. Czerniak, Andrew Futreal, Anirban Maitra, Alexander Lazar, Humam Kadara, Amir A. Jazaeri, Xiangdong Cheng, Jaffer Ajani, Jianjun Gao, Jian Hu, Linghua Wang
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Recent advances in spatial transcriptomics (ST) techniques provide valuable insights into cellular interactions within the tumor microenvironment (TME). However, most analytical tools lack consideration of histological features and rely on m
Externí odkaz:
https://doaj.org/article/dd6c8079518149ec919676d74198ca4c
Autor:
Jane E. Rogers, Jaffer Ajani
Publikováno v:
Current Oncology, Vol 31, Iss 2, Pp 769-777 (2024)
Gastric adenocarcinoma (GAC) continues to be a prevalent worldwide malignancy and a leading cause of cancer death, and it is frequently cited as incurable. Targeted therapy in GAC has lagged behind other solid tumors. The human epidermal growth facto
Externí odkaz:
https://doaj.org/article/5fdd952ed7b447f5a436580c7a9a7cd4
Autor:
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya‐Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcino
Externí odkaz:
https://doaj.org/article/59c4231e83f941f6a4719927e06f1ef1
Autor:
Guangchun Han, Guoliang Yang, Dapeng Hao, Yang Lu, Kyaw Thein, Benjamin S. Simpson, Jianfeng Chen, Ryan Sun, Omar Alhalabi, Ruiping Wang, Minghao Dang, Enyu Dai, Shaojun Zhang, Fengqi Nie, Shuangtao Zhao, Charles Guo, Ameer Hamza, Bogdan Czerniak, Chao Cheng, Arlene Siefker-Radtke, Krishna Bhat, Andrew Futreal, Guang Peng, Jennifer Wargo, Weiyi Peng, Humam Kadara, Jaffer Ajani, Charles Swanton, Kevin Litchfield, Jordi Rodon Ahnert, Jianjun Gao, Linghua Wang
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-19 (2021)
The molecular mechanisms of resistance to immune checkpoint therapy remain elusive. Here, the authors perform immunogenomic analysis of TCGA data and data from clinical trials for antiPD-1/PD-L1 therapy and highlight the association of 9p21 loss with
Externí odkaz:
https://doaj.org/article/f000b69e3fbd4f02bc414de145aab9e8
Autor:
Omkara Lakshmi Veeranki, Zhimin Tong, Alicia Mejia, Anuj Verma, Riham Katkhuda, Roland Bassett, Tae-Beom Kim, Jing Wang, Wenhua Lang, Barbara Mino, Luisa Solis, Charles Kingsley, William Norton, Ramesh Tailor, Ji Yuan Wu, Sunil Krishnan, Steven H. Lin, Mariela Blum, Wayne Hofstetter, Jaffer Ajani, Scott Kopetz, Dipen Maru
Publikováno v:
Disease Models & Mechanisms, Vol 12, Iss 12 (2019)
Mouse models of gastroesophageal junction (GEJ) cancer strive to recapitulate the intratumoral heterogeneity and cellular crosstalk within patient tumors to improve clinical translation. GEJ cancers remain a therapeutic challenge due to the lack of a
Externí odkaz:
https://doaj.org/article/c8c0cfc3d13c42e8a428a009925cdd42
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-7 (2017)
Abstract Gastric cancer is the third most common cause of cancer death worldwide, although it is not in the top 10 causes of cancer death in Northern America. Due to clear differences in incidence, screening, risk factors, tumor biology, and treatmen
Externí odkaz:
https://doaj.org/article/bf31d2d601504825818bf5ff99927ed2
Autor:
Gordon B. Mills, Waun Ki Hong, Ju-Seog Lee, Jaffer Ajani, Vikas Kundra, Murali Ravoori, Yiling Lu, Dong Zhang, Hassan Hall, Kwai Wa Cheng, Catherine Nguyen-Charles, Dimitra Tsavachidou, Jennifer B. Dennison, Jiyong Liang, Eun Sung Park, Jae-Ho Cheong
PDF file - 1.5MB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::692764687091dba98f366b8e82fb118d
https://doi.org/10.1158/1535-7163.22496647
https://doi.org/10.1158/1535-7163.22496647
Autor:
Andrew H Ko, Kyu-Pyo Kim, Jens T Siveke, Charles D Lopez, Jill Lacy, Eileen M O’Reilly, Teresa Macarulla, Gulam A Manji, Jeeyun Lee, Jaffer Ajani, Maria Alsina Maqueda, Sun-Young Rha, Janet Lau, Nedal Al-Sakaff, Simon Allen, Danny Lu, Colby S Shemesh, Xinxin Gan, Edward Cha, Do-Youn Oh
Publikováno v:
The Oncologist.
BackgroundThe MORPHEUS platform comprises multiple open-label, randomized, phase Ib/II trials designed to identify early efficacy and safety signals of treatment combinations across cancers. Atezolizumab (anti-programmed cell death 1 ligand 1 [PD-L1]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5469daa13a550c4eb679ee2b72cc227d
https://doi.org/10.1093/oncolo/oyad022
https://doi.org/10.1093/oncolo/oyad022
Publikováno v:
F1000Research, Vol 7 (2018)
Gastric adenocarcinoma (GAC) is one of the most aggressive malignancies and has a dismal prognosis. Therefore, multimodality therapies to include surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy are needed to provide adva
Externí odkaz:
https://doaj.org/article/97490afea57141dc88ef1170d9e181fa
Autor:
Jordan R. Kharofa, Greg Yothers, Lisa A. Kachnic, Jaffer Ajani, Joshua E. Meyer, Mark E. Augspurger, Gordon S. Okawara, Madhur K. Garg, Tracey E. Schefter, Todd A. Swanson, Desiree E. Doncals, Hyun Kim, Bassem I. Zaki, Samir Narayan, R. Jeffery Lee, Harvey J. Mamon, Michael A. Schwartz, Jennifer Moughan, Christopher H. Crane
Publikováno v:
Am J Clin Oncol
IMPORTANCE: Novel toxicity metrics that account for all AE grades and frequency of events within a grade may enhance toxicity reporting in clinical trials. OBJECTIVES: To evaluate the feasibility of using the Toxicity Index (TI) methodology in two pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7f06550fc5beb52edd859e3299286ce
https://pubmed.ncbi.nlm.nih.gov/36413683
https://pubmed.ncbi.nlm.nih.gov/36413683